Containment & Isolation White Papers & Case Studies

1. Drastically Reduced Isolator Decontamination Cycles 2/28/2013

   With the use of catalytic aeration, M + P is able to reduce the duration of the aeration phase in isolators by about 50 %. The aeration phase is the most time consuming cycle during H2O2 decontamination. By Felix Henning, Optima Packaging Group GmbH 

2. Emerging Fourth Generation Pharmaceutical Containment Technologies 2/25/2013

   Barrier technology has become overwhelmingly accepted as the basis for new aseptic processing facilities in 2013. The traditional clean room facilities of the 20th century are being rapidly replaced with advanced barrier based technology filling facilities. This technological evolution is dramatically reducing the risk of product contamination and risk of infection to patients. By Sterling Kline, RA IPS

3. A High Volume Process For Highly Potent (HP) Active Pharmaceutical Ingredients (APIs) 2/20/2013

   This case study demonstrates how a commercial manufacturing partnership between Alkermes Contract Pharma Services (Alkermes) and a large pharmaceutical company resulted in the establishment of a high volume process for Highly Potent (HP) Active Pharmaceutical Ingredients (APIs).

4. Alternatives to Traditional Fume Hoods: Ductless Enclosures And Fume Hoods 12/20/2012

   Safety is the primary purpose of any filtered enclosure or ventilated fume hood. In most situations, fume hoods remain the equipment of choice for ventilating hazardous airborne chemicals from the laboratory. By Gary Roepke, Senior Project Engineer, Labconco Corporation

5. Laboratory Fume Hood Conflict "Energy Savings" vs "Safe Containment" 12/20/2012

   Safety is the primary purpose of any laboratory hood. Facility managers and laboratory planners desire fume hoods that can conserve energy without compromising safety. Exhausting less air through a hood can result in substantial energy savings.

6. The XPert Nano Enclosure's Ability To Contain Nanoparticles Is NANOSAFE TESTED™ 12/20/2012

   NANOSAFE INC., an independent testing company, evaluated the XPert Nano Enclosure for its ability to contain nanoparticles.

7. Robotics And Isolator-Barrier Systems: The Perfect Combination For Advanced Aseptic Processing 11/27/2012

   The aim of advanced aseptic processing is the elimination and absolute control of all sources of contaminants – most importantly, humangenerated contamination. By Joshua Russell

8. Biological Contamination Events In Isolators: What Lessons Can Be Learned? 8/17/2012

   Microbiological deviation and biological contamination events have been observed in pharmaceutical isolators including those used in production, sterility test and pharmacy aseptic services. By James Drinkwater, Bioquell UK Process & Compliance Director

9. Containing Potent Pharmaceutical Powders - A Strategy Guide 4/23/2012

   With the rise in popularity of High Potency Active Pharmaceutical Ingredients (HPAPIs) there has come increased interest in the containment and safe manufacture of such compounds. As drugs become more potent, they become increasingly dangerous to the health of plant personnel and manufacturers face significant challenges in ensuring the protection of their workers. By Mina Ibrahim, P.Eng., MBA

10. The Logistics Of Filling And Freeze Drying Using Multiple Isolators 1/18/2012
    The use of isolator technology to fill and lyophilize pharmaceuticals presents many logistical challenges. Aventis Pasteur has developed procedures to fill, partially stopper, freeze-dry and cap its products in the Pilot Plant using three isolators (Transfer, Filling, and Lyophilizer).